SELLAS Life Sciences Group Announces Upcoming Presentation Of Phase 2 …
In addition, SELLAS announced today that ZELTHERVA has been formally accepted by the U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research as the proprietary name for SELLAS ‘s WT1 vaccine is a late clinical-stage cancer immu…